Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 209

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 8
Chunk 209
---
 months ended September 30, 2025 compared to the three months ended September 30, 2024 was primarily driven by the sale of the Vorasidenib Royalty Rights and the receipt of the Vorasidenib Milestone Payment in the three months ended September 30, 2024 discussed above in Overview, partially offset by the income tax expense in the three months ended September 30, 2024 as a result of the income related to the Vorasidenib Royalty Rights and Vorasidenib Milestone Payment.

Net (Loss) Income - Nine Months Ended September 30, 2025 vs. Nine Months Ended September 30, 2024 – The increase in net loss for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024 was primarily driven by the sale of the Vorasidenib Royalty Rights and the receipt of the Vorasidenib Milestone Payment in the nine months ended September 30, 2024 discussed above in Overview, partially offset by the income tax expense in the nine months ended September 30, 2024 as a result of the income related to the Vorasidenib Royalty Rights and Vorasidenib Milestone Payment.

Liquidity and Capital Resources

Sources of Liquidity

Since our inception, and through March 31, 2021, we financed our operations primarily through proceeds from the sale of our royalty rights, commercial sales of TIBSOVO®, funding received from our collaboration agreements, private placements of our preferred stock, our initial public offering of our common stock and concurrent private placement of common stock to an affiliate of Celgene, and our follow-on public offerings. Following the sale of our oncology business to Servier on March 31, 2021, we have financed and expect to continue to finance our operations primarily through cash on hand, potential royalty payments with respect to the Retained Earn-Out Rights, the actual and potential future sales of PYRUKYND® and, potentially, collaborations, strategic alliances, licensing arrangements and other nondilutive strategic transactions. In addition, we may pursue opportunistic debt offerings, and equity or equity-linked offerings.

On March 31, 2021, we completed the sale of our oncology business to Servier. The transaction included the sale of our oncology business, including TIBSOVO®, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs